858 Therapeutics and OpenBench Launch Small Molecule Drug Discovery Collaboration

– Partnership will leverage OpenBench’s AI-enabled screening platform to complement 858’s early discovery efforts – SAN DIEGO & SAN FRANCISCO–(BUSINESS WIRE)–858 Therapeutics and OpenBench today announced a collaboration to discover small molecule inhibitors using OpenBench’s structure-based machine learning platform. The collaboration will focus initially on an undisclosed target nominated by 858 Therapeutics. Under the terms…